An open-label, multi-centre, extension study evaluating the long-term safety and tolerability of degarelix one-month depots in patients with prostate cancer. [EXTENSION OF 700040542]
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 17 Apr 2013 Planned number of patients changed from 130 to 137 as reported by German Clinical Trials Register.
- 18 Dec 2009 Status changed from active, no longer recruiting to completed.
- 26 Feb 2007 Interim results have been reported.